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ABSTRACT
There is currently no uniform definition of cutaneous
lupus erythematosus (CLE) upon which to base a
study population for observational and interventional
trials. A preliminary questionnaire was derived from
and sent to a panel of CLE experts which demonstrated
consensus agreement that (1) there is a need for new
definitions for CLE (2) CLE is distinct from systemic
lupus erythematosus and that a CLE grouping scheme
should remain apart from current systemic lupus
erythematosus schema (3) current CLE grouping
schemes are inadequate around communication,
prognostic information and to meet the needs of
researchers, clinicians, patients and payers.
BACKGROUND/INTRODUCTION
Cutaneous lupus erythematosus (CLE)
remains an ill-deﬁned set of disorders, often
grouped together based on common clinical
features, histopathological ﬁndings, labora-
tory abnormalities, association with under-
lying systemic lupus erythematosus (SLE) or
combinations thereof. In 1981, Dr James
Gilliam and Dr Richard Sontheimer pro-
posed a grouping ‘classiﬁcation’ schema to
deal with the heterogeneity inherent to this
set of disorders.1 Since that time, a variety of
other grouping schemes have been proposed
with variable uptake by the medical and sci-
entiﬁc communities invested in CLE. There
is currently no uniform deﬁnition of CLE
upon which to base a study population for
observational and interventional trials. This
has led to inconsistency among studies in the
ﬁeld. In addition, the current grouping
systems are heterogeneous, inconsistent, and
none have been formally adopted by the
‘expert’ community of investigators and clini-
cians committed to these disorders.
At the 3rd International Meeting on
Cutaneous Lupus Erythematosus (ICCLE)
held May 2013 in Edinburgh, Scotland, a
scientiﬁc meeting was called at which
nominal groups of international CLE experts
were formed around stating the need for
change and to generate item lists that charac-
terise CLE. Facilitated, open-ended concept-
mapping and brain-storming sessions were
used to generate these item lists. The
expressed goal was to agree upon an
approach to consensus around (1) uniform
deﬁnition(s); (2) grouping schemes; and (3)
clarifying an understanding of the complex
relationship between cutaneous and systemic
disease involvement. Based on the input
from the ICCLE meeting key stakeholder
groups were deﬁned, lists of CLE-deﬁning
characteristics were generated and the use of
a Delphi consensus method was agreed
upon.
The Delphi technique is a method of
consensus-building using a series of iterative
questionnaires to collect data from a panel of
selected experts/stakeholders in a given area
of interest. The iterative nature of the
process, together with controlled anonymous
feedback at each questionnaire stage, subject
anonymity and a predeﬁned stop criterion,
allow convergence towards a consensus
‘answer’.2 3 There are many examples of rele-
vant Delphi exercises in this area of the ﬁeld,
including a Delphi consensus process
around the development of classiﬁcation cri-
teria for systemic sclerosis using experts in
this disease state.4
In follow-up to the ICCLE meeting, a
‘pre-Delphi’ questionnaire was put forth to a
relevant stakeholder group including paedi-
atric and adult dermatologists, rheumatolo-
gists and dermatopathologists. The goal of
this questionnaire was to further build a data-
base of international participant stakeholders
and more broadly query the relevant partici-
pant pool regarding the need for uniform
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deﬁnitions, revision of grouping schema and deﬁning
the CLE/SLE relationship as an expert community.
METHODS
Figure 1 describes a process overview beginning with the
ICCLE meeting. Invitations to complete the 12-question
survey were sent to 81 expert participants. The 12 ques-
tions presented were those outlined and agreed upon by
the concept-mapping process by the participants at the
ICCLE meeting. Survey results were collected anonym-
ously over a 3 month period. Descriptive statistics were
used to evaluate responses: the median score is reported
as the preferred measure in a Delphi process
(a measure of central tendency that is minimally dis-
torted by outliers). Survey responses were graded on a
continuous scale from 0 to 100 (0=complete disagree-
ment with the proposed statement, 50=neutral response,
100=complete agreement with the proposed statement).
A median response of 70 or greater was predeﬁned as
‘consensus agreement’, a median response of 30 or
lower was predeﬁned as ‘consensus disagreement’,
median scores between 30 and 70 were predeﬁned as
‘no consensus’ among participants.
The survey questionnaire was designed and implemen-
ted using RedCAP software.5
RESULTS
The survey response rate was (n=60/81) 74% with a
group comprised predominantly of dermatologists
(n=58, 96.7%); rheumatologists (n=5, 8.3%), dermato-
pathologists (2, 3.3%). Paediatric subspecialists were
lacking in the initial survey. Survey participants self-
reported their geographic location to be: North America
(n=39, 65%), Europe (n=15, 25%), Asia (4, 6.7%),
South America (n=1, 1.7%), Africa (n=1, 1.7%). The
Middle East and Australia were not represented in the
initial survey.
Table 1 demonstrates the median and per cent of
respondents by agreement for each of the 12 questions
posed. Based on prespeciﬁed consensus criteria as
noted above, there is consensus agreement on two-thirds
of the survey items: questions 1, 3–6, 8, 9 and 12.
Complete agreement is highest for question 1 (46.7%),
question 6 (45.8%) and question 4 (45.0%). Consensus
disagreement was found to questions 2 and 7, though
variability is high for both (IQR of 67.0 and 49,
Figure 1 Summary flow diagram leading to pre-Delphi exercise.
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respectively). Of the respondents 22.4% completely dis-
agree with question 2. No consensus was found to ques-
tions 10 and 11. Details of the data distribution of each
question are found in the histogram distribution of scores
(ﬁgure 2).
DISCUSSION AND FUTURE DIRECTIONS
Interpretation of the survey results presented above may
be best described in three thematic groups: (1) the
need for new deﬁnitions of CLE (questions 8, 9, 12) (2)
the need to better clarify/deﬁne the relationship
between CLE and SLE (1, 2, 3) (3) the need to re-evaluate
current disparate grouping schema (4–7, 10, 11). There
was consensus among this group of questions, indicating
that the expert panel of participants agreed that there is a
need for new deﬁnitions for CLE as current deﬁnitions
impede communication between physician colleagues and
in physician-patient interactions. With regards to the
CLE-SLE relationship, there was consensus agreement
that CLE is distinct from SLE and that a CLE grouping
scheme should remain apart from current SLE schema
which otherwise include mucocutaneous disease items.
Finally, with regards to the current grouping schema,
there was consensus that the current schemes are inad-
equate around communication, prognostic information
and to meet the needs of researchers, clinicians, patients
and payers. However among this question pool, there
Table 1 Median and per cent of respondents by agreement
Median
(IQR)
% Completely
agree
(100%)
% Agree
(70–99)
% Neither
agree nor
disagree
(31–69)
% Disagree
(1–30)
% Completely
disagree (0)
n (%)
1. Defining CLE as distinct from SLE
is important.
98.0 (15.5) 28 (46.7) 23 (38.3) 5 (8.3) 4 (6.7) 0 (0.0)
2. CLE is SLE involving the skin in all
cases of CLE.
15.0 (67.0) 5 (8.6) 9 (15.5) 5 (8.6) 26 (44.8) 13 (22.4)
3. Patients without serious end organ
involvement, but who meet SLE
criteria, should be part of a CLE
grouping scheme.
89.0 (24.5) 11 (19.6) 35 (62.5) 5 (8.9) 3 (5.4) 2 (3.6)
4. Classification schemes of CLE are
important for communication with
patients and between physicians.
99.0 (11.5) 27 (45.0) 28 (46.7) 4 (6.7) 1 (1.7) 0 (0.0)
5. Grouping schemes of CLE are
important to convey prognosis to
patients.
95.0 (25.0) 22 (36.7) 29 (48.3) 6 (10.0) 3 (5.0) 0 (0.0)
6. A single international classification
scheme is needed to enable
communication with patients and
physicians.
98.0 (20.0) 27 (45.8) 27 (45.8) 5 (8.5) 0 (0.0) 0 (0.0)
7. The current cutaneous lupus
grouping systems are adequate to
meet the needs of researchers,
clinicians, patients and payers.
30.0 (49.0) 3 (5.4) 10 (17.9) 14 (25.0) 22 (39.3) 7 (12.5)
8. Regarding communication: there
exists confusion when discussing
these disorders with patients.
83.0 (26.0) 12 (20.3) 35 (59.3) 6 (10.2) 6 (10.2) 0 (0.0)
9. Regarding communication: there
exists confusion when discussing
these disorders with physicians.
86.5 (22.0) 16 (26.7) 39 (65.0) 3 (5.0) 2 (3.3) 0 (0.0)
10. Current grouping schemes are
adequate to inform about risks
during pregnancy.
53.0 (49.0) 0 (0.0) 21 (36.8) 16 (28.1) 18 (31.6) 2 (3.5)
11. The current grouping schemes (at
present) are adequate for
informing treatment decisions.
45.0 (46.0) 2 (3.6) 12 (21.8) 20 (36.4) 19 (34.5) 2 (3.6)
12. Cutaneous lupus is ill-defined and
needs to be formally defined by
expert consensus.
85.0 (34.0) 19 (32.2) 25 (42.4) 11 (18.6) 3 (5.1) 1 (1.7)
CLE, cutaneous lupus erythematosus; SLE, systemic lupus erythematosus.
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was no consensus agreement that the current grouping
schemes affected treatment decisions or failed to inform
about risks during pregnancy. The pre-Delphi exercise
was largely about establishing (1) where confusion and
gaps exist around CLE terminology (2) prioritising the
group’s efforts with regards to where we will focus our
resources moving forward with the Delphi process. We
hope that this article will encourage other relevant stake-
holders in the CLE Delphi process to come forward and
take part in helping to improve the inconsistencies in
the ﬁeld. Each of the general themes build upon one
another and because the pre-Delphi exercise has
demonstrated consensus that even deﬁnitions are
lacking, we will begin with a stepwise approach (A)
deﬁnitions (B) grouping schemes/‘classiﬁcation cri-
teria’ (C) ‘diagnostic criteria’. Building on these
results, the steering committee has moved to proceed
with a formal Delphi consensus process with an initial
focus on ‘deﬁning CLE’, which should be a good platform
for the subsequent processes to achieve an inter-
national classiﬁcation scheme. In the vasculitis litera-
ture, analogous processes have been used successfully
to ﬁrst deﬁne, then build classiﬁcation and diagnostic
criteria.6 These same processes may later expand to
include diagnostic, classiﬁcation criteria as well as out-
comes measures (distinct from SLE diagnostic and clas-
siﬁcation systems), such as those modelled by the
OMERACT group for developing outcome measures in
rheumatoid arthritis.7
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